Kamal S. Saini, Executive Medical Director and Head of European Oncology Team at Fortrea, shared a post on LinkedIn about a paper he co-authored with colleagues, published in Immunotherapy:
“NSCLC real-world data from India, in collaboration with Dr Ullas Batra and his distinguished team: ‘First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap’. Out now in Immunotherapy (Taylor and Francis Group).
78 patients with advanced NSCLC received pembrolizumab-based first-line therapy, and after a median follow-up of 27 months, median OS was 21 months and median PFS was 6.3 months. Real-world LMIC data demonstrated comparable effectiveness of pembrolizumab-based therapy in mNSCLC despite a higher proportion of adverse prognostic factors.”
Title: First-line pembrolizumab for metastatic NSCLC in lower-middle-income countries: bridging the efficacy-effectiveness gap
Authors: Ullas Batra, Mansi Sharma, Alexis Andrew Miller, Kundan Singh Chufal, Irfan Ahmad, Abhinav Dewan, Sabeena Chowdhary, BP Amrith, Rashi Sachdeva, Vanshika Batra, Preetha Umesh, Kratika Bhatia, Shrinidhi Nathany, Anurag Mehta, Paulo Nunes Filho, Khaled Tolba, Isagani M Chico, Laura Vidal Boixader, Luca Cantini, Kamal S Saini
You can read the Full Article in Immunotherapy.
More posts featuring Kamal S. Saini.